NASDAQ: YARWYarrow Bioscience Inc Stock
$30.45+2.40 (+8.56%)
Updated Jul 29, 2026
YARW Price
$30.45
Fair Value Price
$23.93
Market Cap
$20.31M
52 Week Low
$14.05
52 Week High
$46.95
P/E
-1.24x
P/B
0.82x
P/S
56.26x
PEG
N/A
Dividend Yield
66.01%
Revenue
$454.00k
Earnings
-$21.46M
Gross Margin
100%
Operating Margin
-4,725.33%
Profit Margin
-4,726.2%
Debt to Equity
0.05
Operating Cash Flow
-$26M
Beta
1.01
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
YARW Overview
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine YARW's potential to beat the market
- YARW doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
YARW
RankedUnranked of 461
RankedUnranked of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $255.97 | A | |
| $11.01 | A | |
| $8.38 | A |
Be the first to know about important YARW news, forecast changes, insider trades & much more!
YARW News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how YARW scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
YARW ($30.45) is overvalued by 27.25% relative to our estimate of its Fair Value price of $23.93 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
YARW ($30.45) is not significantly undervalued (27.25%) relative to our estimate of its Fair Value price of $23.93 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
YARW is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more YARW due diligence checks available for Premium users.
Valuation
YARW fair value
Fair Value of YARW stock based on Discounted Cash Flow (DCF)
Price
$30.45
Fair Value
$23.93
Overvalued by
27.25%
YARW ($30.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
YARW ($30.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
YARW is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
YARW price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.24x
Industry
23x
Market
18.12x
YARW price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.82x
Industry
5.35x
YARW is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
YARW's financial health
Profit margin
Revenue
$86.0k
Net Income
-$3.6M
Profit Margin
-4,168.6%
YARW's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
YARW's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$25.9M
Liabilities
$1.2M
Debt to equity
0.05
YARW's short-term assets ($25.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
YARW's short-term assets ($25.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
YARW's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
YARW's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.1M
Investing
$4.7M
Financing
-$15.0k
YARW's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
YARW vs Biotech Stocks
Yarrow Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.